Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party

Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party

Abstract Pure red cell aplasia (PRCA) is a relevant complication after ABO-mismatched allogeneic hematopoietic cell transplantation (HCT). No standard treatment exists, and practice is heterogenous. In this study, we took advantage of an international collaboration to describe characteristics and ou...

Full description

Saved in:
Bibliographic Details
Main Authors: Nico Gagelmann, Moniek de Witte, Christophe Peczynski, William Boreland, Annoek E. C. Broers, Edgar Jost, Alexander Kulagin, Albert Esquirol, Simona Sica, Jürgen Kuball, Gerardo Errico, Wolfgang Bethge, Johan Maertens, Friedrich Stölzel, Edouard Forcade, Matthew Collin, Matteo Parma, Goda Choi, Nicolaus Kröger, Maria Chiara Di Chio, Maria Chiara Finazzi, Lucia López Corral, Jose Rifón, Alberto Mussetti, Adrian Bloor, Marco Ladetto, Hélène Schoemans, Olaf Penack, Ivan Moiseev, Zinaida Peric
Format: Article
Language:English
Published: Nature Publishing Group 2025-06-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-025-01315-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41408-025-01315-8

Similar Items